hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

hVIVO PLC
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Accounts Receivables
ÂŁ20.4m
CAGR 3-Years
31%
CAGR 5-Years
32%
CAGR 10-Years
37%
Oxford Nanopore Technologies PLC
LSE:ONT
Accounts Receivables
ÂŁ34.6m
CAGR 3-Years
-12%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Accounts Receivables
ÂŁ5.3m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Accounts Receivables
ÂŁ214k
CAGR 3-Years
-17%
CAGR 5-Years
-30%
CAGR 10-Years
-19%
Ergomed PLC
LSE:ERGO
Accounts Receivables
ÂŁ31.3m
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Accounts Receivables
ÂŁ9.3m
CAGR 3-Years
146%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Accounts Receivables?
Accounts Receivables
20.4m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Accounts Receivables amounts to 20.4m GBP.

What is hVIVO PLC's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
37%

Over the last year, the Accounts Receivables growth was 105%. The average annual Accounts Receivables growth rates for hVIVO PLC have been 31% over the past three years , 32% over the past five years , and 37% over the past ten years .

Back to Top